Astrazeneca (AZN) Capital Expenditures (2009 - 2026)

Astrazeneca has reported Capital Expenditures for 18 years, with the latest figure at -$763.0 million in Q2 2026.

• On a quarterly basis, Capital Expenditures fell 15.78% year-over-year to -$763.0 million in Q2 2026; TTM through Jun 2026 was -$3.0 billion, a 37.01% decrease from a year earlier, with the FY2025 full-year figure at -$2.8 billion, down 46.05% from the prior year.
• Capital Expenditures was -$763.0 million for Q2 2026 at Astrazeneca, down from -$547.0 million in the prior quarter.
• The five-year high for Capital Expenditures was -$219.0 million in Q1 2022, with the low at -$1.0 billion in Q4 2025.
• Average Capital Expenditures over 5 years is -$502.4 million, with a median of -$423.0 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2025: Capital Expenditures grew 12.15% in 2022, then sank 72.51% in 2025.
• Over 5 years, Capital Expenditures stood at -$253.0 million in 2022, then declined by 6.72% to -$270.0 million in 2023, then plunged by 162.22% to -$708.0 million in 2024, then sank by 46.33% to -$1.0 billion in 2025, then climbed by 26.35% to -$763.0 million in 2026.
• The last three Capital Expenditures figures came in at -$763.0 million (Q2 2026), -$547.0 million (Q1 2026), and -$1.0 billion (Q4 2025), per Business Quant data.